Background: The purpose of this study was to determine the impact of CT-determined pretreat-
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respectively; P 5 .003). Five-year OS for patients with tumor volumes 21 cm 3 in the cohort treated with total laryngectomy followed by radiotherapy (RT; n 5 42 of 83) was not statistically significant when compared to <21 cm 3 (50% vs 63%, respectively; P 5 .058). On multivariate analysis, tumor volume 21 cm 3 was a significant independent correlate of worse disease-specific survival (DSS; P 5 .004), event-free survival (P 5 .005), recurrence-free survival (RFS; P 5 .04), noncancer cause-specific survival (P 5 .02), and OS (P 5 .0002).
Conclusion: Pretreatment CT-based tumor volume is an independent prognostic factor of outcomes in T4a laryngeal cancer.
K E Y W O R D S
outcomes, radiotherapy, survival, T4a, tumor, volume, volumetry
| I N T R O D U C T I O N
Treatment for advanced-stage laryngeal squamous cell carcinoma (SCC) has been shifted toward nonsurgical strategies with the introduction of organ-preservation modalities. This was motivated by the landmark study of the Department of Veterans Affairs (VA) Laryngeal
Cancer Study Group reporting that larynx preservation with induction chemotherapy followed by radiotherapy (RT) can be effective in preserving the larynx without compromising overall survival (OS). 1 Furthermore, the Radiation Therapy Oncology Group protocol 91-11 demonstrated that concurrent chemoradiotherapy (CRT) resulted in superior larynx preservation rates and local control in patients with advanced laryngeal cancer. 2 These prospective studies provided strong evidence that well-selected, therapy-responsive patients with advanced laryngeal cancer may be treated effectively with organpreservation strategies.
In addition to survival, the morbidity from functional loss of laryngeal speech and permanent tracheostoma required after total laryngectomy is a foremost concern of clinicians when selecting the treatment modality. 3 Selecting the optimal treatment strategy remains a dilemma in advanced laryngeal cancer, in part because objective prognostic parameters remain unclear. 4, 5 The American Joint Committee on Cancer TNM staging classification schema is a universally accepted prognostic system for treatment for head and neck cancer. 6 TNM classification utilizes the maximum diameter and anatomic extent of the primary tumor, number and size of involved regional lymph nodes, and the presence of distant metastases. Conceptually, the current laryngeal cancer system is designed from a historical surgical paradigm, and is a surrogate for surgical resectability and functional laryngeal impairment. However, clinical, pathologic, imaging, and molecular parameters have not been incorporated into the staging system for prognostic significance in head and neck cancer as a quantitative measure for expectation of RT-related outcomes. Maximum diameter and anatomic extensions of the TNM classification system are nonvolumetric and measured in a single axis clinically or pathologically, and, thus, are not actual measurements of the number of tumor clonogens, although efforts have been made to utilize tumor volumetric measurements to predict the response to treatment. 7 Tumor volume is easily measured by CT, and, as a quantitative parameter, displays more granular predictive capacity than TNM classification alone. 8, 9 Previous data analyzing imaging-derived tumor volumetry in patients with laryngeal SCC has prognostic significance. [10] [11] [12] Greater pretreatment tumor volume has been associated with a higher chance of recurrence after radiotherapy. 13, 14 Despite promise that tumor volume may be a prognosticator, tumor measuring volumes and cutoff values vary widely. Site-specific and stage-specific studies are imperative to clarify the role of tumor volume on treatment outcomes for surgical and nonsurgical modalities considering the responses to treatment of the diverse anatomic sites of invasion.
Few studies have investigated the prognostic role of primary tumor volume in patients with advanced laryngeal SCC. [15] [16] [17] [18] Additional studies, including a large uniform cohort of patients, are needed. Given these considerations, we hypothesize that the tumor volume may be prognostic of survival in patients with advanced laryngeal SCC. To this end, we aim to investigate the impact of tumor volume on disease control and survival in a uniform cohort of patients with T4a laryngeal SCC. 
| MATERIALS A ND METHODS

| Study population
| Statistical analysis
Log-rank tests were used to compare univariate survival curves between the larynx preservation and total laryngectomy and postoperative radiation therapy (total laryngectomy-PORT) groups. Univariate and multivariate Cox proportional hazards assessments were performed to investigate the impact of the following variables with disease control and/or survival endpoints: age, sex, ethnicity, subsite of origin, ECOG performance status, nodal positivity, surgical treatment, radiation dose, and tumor volume. Abbreviations: CRT, chemoradiotherapy; IMRT, intensity-modulated radiotherapy; RT, radiotherapy.
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Recursive partitioning analysis (RPA) was used to determine a cutoff point of tumor volume associated with OS. Kaplan-Meier curves were subsequently plotted for groups above and below the RPA-derided cutoff point. Log-rank tests were used to compare OS in both groups. All statistical analyses were performed using JMP 12.0 Pro statistical software (SAS Institute, Cary, NC), with a specified alpha of 0.05.
| R E S U LTS
| Patient and treatment characteristics
A total of 124 patients were identified with previously untreated T4a laryngeal SCC. The median age at the time of initial diagnosis was 58 years (range 36-91 years), and 101 were men (81%). The majority of tumors were of supraglottic origin (53%). Table 1 summarizes patient, disease, and treatment characteristics. Forty-one patients (33%) were treated with larynx preservation approaches and 83 patients (67%) underwent total laryngectomy-PORT. In regard to RT delivery, 56 patients (45%) received 2D/3D conformal, and 68 patients (55%) received intensity-modulated radiotherapy (IMRT).
| Tumor volume assessment
The mean tumor volume from all 124 patients was 29.0 6 36.8 cm 
| Correlates of survival
The median follow-up was 48.5 months (range 6-158 months) for all patients and 68 months (range 9-159 months) for surviving patients.
The 5-year OS rate was 54%. The 5-year locoregional control and distant metastasis-free survival rates were 80% and 71%, respectively. Table 2 ).
| Therapy cohorts
There was no significant difference in mean tumor volume between patients treated with larynx preservation and total laryngectomy-PORT (27.9 vs 29.5 cm 3 , respectively; P 5 .2). The distribution of patient and disease characteristics, as well as the type of invaded surrounding structures for both therapy cohorts is presented in Supporting Information Table S1 . When assessing competing causes of survival, cancer-related death predominated during the entire follow-up period for patients treated with total laryngectomy-PORT or larynx preservation ( Figure 3 ).
The 5-year OS rates of the larynx preservation-RT cohort were not statistically different compared to the total laryngectomy-PORT cohort (50% vs 56%; P 5 .7). Using the RPA-derived cutoff of 21 cm Figure S1 ). For the larynx preservation cohort, patients with tumor volume <21 cm 3 also had better 5-year laryngoesophageal dysfunction-free survival compared with patients with tumor volume 21 cm 3 (38% vs 15%; P 5 .02).
| Tumor volume and survival endpoints
Results of a multivariate analysis for all survival endpoints are shown in Figure 5 . Table 4. 14-18,25-29,31-39 LRR, locoregional recurrence; MFS, metastasis-free survival; NS, not specified; OS, overall survival; PEG, percutaneous endoscopic gastrostomy; PFS, progression-free survival; PORT, postoperative radiotherapy; RC, regional control; RT, radiotherapy.
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Broadly, and in concert with our data, the suggestion that a CT- (Table 4) 14 -18,25-29,31-39 showed correlation between tumor volume and outcomes across surgical and nonsurgical laryngeal cohorts, across subsites, and stages. Notably, our study included a well selected, homogenous cohort of patients with T4a laryngeal SCC to identify a tumor volume "threshold" specific to this group of patients, contrary to other studies that reported tumor volume cutoffs of mixed head and neck cancer subsites and stages, precluding its applicability as a prognostic parameter in specific disease subgroups.
The limitations of this study, however, include a retrospective single-institution design, with all requisite caveats. In addition, patients included in this study received heterogeneous treatment approaches based on clinical multidisciplinary judgment, rather than randomization or uniform approaches, allowing individualized therapy, but introducing potential bias. For example, a sizable portion of our patients was treated with surgery followed by PORT, whereas comparatively fewer patients were treated with a larynx preservation approach. Volumetric measurements, although quality-assured to the best degree possible, inherently suffer from potential measurement variability resulting from operator dependent intraobserver and interobserver delineation bias components. Nevertheless, to the best of our knowledge, this is the largest study to examine the prognostic value of tumor volume in the specific subgroup of patients with T4a laryngeal SCC.
In summary, our data, in concert with previous extensive longterm historical data, point to the potential perils of nonsurgical therapy for patients with T4 laryngeal cancer. Surgery remains the cornerstone of therapy for patients with T4 laryngeal SCC, and we heavily emphasize that volumetry alone should not be used for treatment selection, but instead, integrated as a component of the decision matrix for these complex cases. Indeed, although volumetry seems to be an independent correlate for oncologic outcomes, any patient on the precipice of post-RT dysfunction should be dispositioned to surgery with PORT regardless of tumor volume, lest an "ornamental" larynx serve as the harbinger of posttherapy aspiration, pneumonia, or iatrogenic death.
Our data do serve to highlight that even a deceptively small volume 
